Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add filters








Year range
1.
Chinese Journal of Biochemical Pharmaceutics ; (6): 194-196, 2017.
Article in Chinese | WPRIM | ID: wpr-511533

ABSTRACT

Objective To study curative efficacy of benazepril combined with atorvastatin on N-terminal pro-brain natriuretic peptide (NT-proBNP) and its efficacy in the treatment of chronic cardiac failure. Methods 90 patients of chronic heart failure were selected as research objects. The control group were treated with benazepril, while the observation group were treated with benazepril combined with atorvastatin, 45 cases in each group. Then before and after treatment of 6 months, the cardiac function of left ventricular end-diastolic dimension (LVEDD), left ventricular end systolic dimension (LVESD), left ventricular eject fraction (LVEF), C-reactionprotein (CRP), interleukin- 6 (IL-6, tumor necrosis factor α (TNF-α) and plasma NT-proBNP levels were compared between two groups, and the efficacy was observed. Results After treatment, LVEDD and LVESD in observation group were lower than those in control group, the LVEF was higher than that in control group(P<0.05). The CRP,IL-6 and TNF-αlevels in observation group were lower than those in control group(P<0.05). The plasma NT-proBNP level in observation group was significantly lower than that in control group(P<0.05). The total effective rate of observation group was statistically higher than that that in the control group 95.55%(43/45)vs. 77.77%(35/45)(P<0.05). Conclusion Benazepril combined with atorvastatin in the treatment of chronic heart failure is significant, can reduce plasma NT-proBNP levels, improve the inflammatory factor.

2.
Asian Pacific Journal of Tropical Medicine ; (12): 682-687, 2016.
Article in English | WPRIM | ID: wpr-819937

ABSTRACT

OBJECTIVE@#To study the effect and mechanism of the dysfunction of CD4(+) T cells in the disease process of chronic cardiac failure (CHF).@*METHODS@#According to different group technologies, 100 CHF patients were divided into the following groups: ischemia group and non-ischemia group, heart function Ⅲ-Ⅳ group and heart function Ⅰ-Ⅱ group, event group and non-event group, and 50 healthy volunteers were included in the control group. Real-time PCR was used to detect transcription factors T-bet and GATA-3 of Th1 and Th2; flow cytometry was applied to determine the ratio of Th17 and Treg cells; ELISA was employed to test cytokines IFN-γ, IL-4, IL-17 and IL-10 of peripheral blood Th1, Th2, Th17 and Treg cells, respectively; ultrasonic cardiogram was used to exploit to LVEF and LVEDd; and electrochemilu minescene immunoassay was used to examine plasma BNP. The differences of all indexes of all groups were analyzed and the correlation between CD4 T cells and clinical indexes was analyzed by Pearson correlation analysis.@*RESULTS@#As compared to the control group, the transcription factors T-bet and GATA-3 of Th1 and Th2, the ratio of cytokines Th17 and IFN-γ, cytokines IL-17, T-bet/GATA-3, IFN-γ/IL-4, Th17 cells/Treg cells, IL-17/IL-10 of the ischemia group and non-ischemia group, heart function Ⅲ-Ⅳ group and heart function Ⅰ-Ⅱ group, event group and non-event group were all increased significantly, while their transcription factor GATA-3 of Th2, cytokines IL-4, Treg cells ratio, cytokines IL-10 were decreased obviously. The differences showed statistical significance (P < 0.05). The increase or decrease of the partial CD4+ T cells of the ischemia group, heart function Ⅲ-Ⅳ group and event group was more distinctly. The results of Pearson correlation analysis showed that IFN-γ and IL-17 were significantly positively correlated with LVEDd and BNP, IL-4 and IL-10 were also significantly positively correlated with LVEF, but correlated negatively with BNP, and IL-17 was negatively correlative with LVEF.@*CONCLUSIONS@#There was a correlation between CHF and the dysfunction of CD4(+) T cells showing immune activation phenomenons of deviations from the Th1/Th2 balance towards Th1 and from the Th17/Treg balance towards Th17, which was also related to the types, severity and prognosis of the disease.

3.
Asian Pacific Journal of Tropical Medicine ; (12): 682-687, 2016.
Article in Chinese | WPRIM | ID: wpr-951374

ABSTRACT

Objective To study the effect and mechanism of the dysfunction of CD4

4.
Chinese Journal of Emergency Medicine ; (12): 379-383, 2013.
Article in Chinese | WPRIM | ID: wpr-437586

ABSTRACT

Objective To study the therapeutic effect and mechanism of enteral nutrition support for treatment of chronic cardiac failure of rats.Methods Ligature of abdominal aorta was used to prepare SD rat model of chronic cardiac failure.The rat models of cardiac failure were randomly (random number) divided into three groups:conventional therapy group,conventional therapy plus enteral nutrition support group and non-therapy group.The rats in conventional therapy group were administrated with routinely used drugs for chronic cardiac failure.The rats in conventional therapy plus enteral nutrition support group were treated with conventionally used medicine plus enteral nutrition liquid.The rats in non-therapy group were given the same amounts of dummy medicine and normal saline.Ultrasonic cardiography,ELISA for detection of atrial natriuretic peptide (BNP) and examination of pathological change in myocardium tissues after HE staining were carried out for comparison of cardiac function of rats with chronic heart failure between pre-and post-treatment.Results The commonly used drug enabled the heart of rats with chronic heart failure to elevate the LVFS (left ventricular fraction shortening) and LVEF (left ventricular ejection fraction) levels (q=3.59,P<0.05; q=4.01,P<0.05),to decrease the BNP in blood plasma (u=2.285,P<0.05) and to lessen the injury of myocardial tissue (u =2.332,P < 0.05).However,compare to the chronic cardiac failure rats administrated with commonly used drug,the chronic cardiac failure rats treated by combination of the commonly used drug and enteral nutrition liquid presented significantly higher LVFS and LVEF levels (q =4.34,P < 0.05 ; q =3.98,P < 0.05),lower plasma BNP level (u =2.548,P <0.02) and milder injury of myocardial tissue (u=2.631,P<0.02).Conclusions The commonly used drug plus enteral nutrition support promotes in higher efficiency the heart function of chronic cardiac failure rats,suggesting that this nutrition support can be used as an adjuvant therapy for patients with chronic cardiac failure in clinic.

5.
Chinese Journal of Rehabilitation Theory and Practice ; (12): 1081-1083, 2006.
Article in Chinese | WPRIM | ID: wpr-977582

ABSTRACT

@#Following the aging of population in the whole world and prolongation of survival time of patients with chronic diseases such as coronary heart disease, hypertension, and etc, the incidence rate of chronic cardiac failure increased obviously, especially its high level lethality rate becomes a big challenge which the clinical cardiologists must face to. As one of important treating methods, rehabilitation therapy has been attracting attention more and more.

6.
Chinese Journal of Information on Traditional Chinese Medicine ; (12)2006.
Article in Chinese | WPRIM | ID: wpr-579860

ABSTRACT

Objective To evaluate the effect of Jiuwei Pingzhi Jiaonang on cardiac function, high-sensitivity C-reactive protein (hs-CRP) and blood lipids in patients with chronic cardiac failure (CHF). Methods Seventy-eight patients were randomly assigned to two groups. The control group (38 cases) was treated with angiotensin converting enzyme inhibitor, ?-receptor inhibitor, digoxin and diuretic, and the treated group (40 cases) with the above treatment plus Jiuwei Pingzhi Jiaonang for six months. The changes of cardiac function and serum hs-CRP were measured by echocardiograph and enhanced immunoturbidimetry respectively before and after treatment. Results Compared with those before treatment, the NYHA cardiac function grade, the left ventricular dimension end diastole and the left ventricular dimension end systole decreased significantly (P

SELECTION OF CITATIONS
SEARCH DETAIL